FRED HUTCHINSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Employees: -

Market Cap: -

Website: https://www.fredhutch.org

Clinical Trials

eHealth Diet and Physical Activity Program for the Improvement of Health in Rural Latino Cancer Survivors

Not Applicable

Terminated

Conditions: Hematopoietic and Lymphoid Cell Neoplasm
Malignant Solid Neoplasm

Interventions: Behavioral: Health Education
Other: Physical Activity
Other: Quality-of-Life Assessment
Other: Questionnaire Administration

First Posted Date: 2019-09-09

Last Posted Date: 2023-07-03

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 20

Registration Number: NCT04081298

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Effects of Alternative Healthy Eating Index-Based Diet on Inflammatory Markers and Breast Density in Healthy Participants

Not Applicable

Completed

Conditions: Healthy Subject

Interventions: Dietary Supplement: Dietary Intervention
Procedure: Dual X-ray Absorptiometry
Other: Questionnaire Administration

First Posted Date: 2019-08-20

Last Posted Date: 2021-01-22

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 21

Registration Number: NCT04062955

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Nozin in Preventing Respiratory Viral Infections in Patients Undergoing Stem Cell Transplant, PREV-NOSE STUDY

Phase 1

Terminated

Conditions: Solid Neoplasm
Hematopoietic and Lymphoid Cell Neoplasm
Malignant Solid Neoplasm

Interventions: Drug: Nozin
Other: Best Practice

First Posted Date: 2019-08-19

Last Posted Date: 2024-11-08

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 10

Registration Number: NCT04060849

Locations: 🇺🇸
University of Chicago Medicine-Orland Park, Orland Park, Illinois, United States
🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Financial Navigation Intervention in Improving Financial and Clinical Outcomes in Patients With Newly Diagnosed Gastric or Gastroesophageal Junction Adenocarcinoma

Not Applicable

Completed

Conditions: Gastric Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma

Interventions: Other: Media Intervention
Other: Best Practice
Other: Informational Intervention
Other: Questionnaire Administration
Other: Quality-of-Life Assessment

First Posted Date: 2019-06-14

Last Posted Date: 2022-10-14

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 30

Registration Number: NCT03986502

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Thiotepa in Treating Patients With Non-malignant Disorders

Phase 2

Recruiting

Conditions: Non-Neoplastic Hematopoietic and Lymphoid Cell Disorder

Interventions: Drug: Thiotepa
Drug: Treosulfan
Drug: Fludarabine Phosphate
Biological: Rabbit Anti-Thymocyte Globulin
Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
Procedure: Bone Marrow Biopsy
Procedure: Bone Marrow Aspiration
Procedure: Magnetic Resonance Imaging
Procedure: Biospecimen Collection

First Posted Date: 2019-06-10

Last Posted Date: 2024-07-23

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 40

Registration Number: NCT03980769

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)

Phase 2

Recruiting

Conditions: Acute Leukemia
Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia
Myelodysplastic Syndrome
Myeloproliferative Neoplasm

Interventions: Radiation: Total-Body Irradiation
Drug: Thiotepa
Drug: Fludarabine
Drug: Cyclophosphamide
Biological: Peripheral Blood Stem Cell
Drug: Tacrolimus
Biological: Allogeneic CD34+-enriched and CD45RA-depleted PBSCs
Drug: Methotrexate
Drug: Cyclosporine
Drug: Busulfan
Drug: Sirolimus
Procedure: Bone Marrow Aspiration and Biopsy
Procedure: Echocardiography
Procedure: Multigated Acquisition Scan
Procedure: Biospecimen Collection

First Posted Date: 2019-05-31

Last Posted Date: 2024-08-22

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 120

Registration Number: NCT03970096

Locations: 🇺🇸
University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States
🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Glucosamine and Chondroitin in Gut in Preventing People From Inflammation

Phase 1

Completed

Conditions: Healthy Subject

Interventions: Dietary Supplement: Glucosamine Sulfate/Chondroitin Sulfate Tablet
Other: Placebo

First Posted Date: 2019-05-24

Last Posted Date: 2019-05-24

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 9

Registration Number: NCT03963323

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Identifying Best Approach in Improving Quality of Life and Survival After a Donor Stem Cell Transplant in Older, Medically Infirm, or Frail Patients With Blood Diseases

Phase 2

Active, not recruiting

Conditions: Hematopoietic and Lymphoid Cell Neoplasm
Non-Neoplastic Hematologic and Lymphocytic Disorder

Interventions: Other: Clinical Management
Other: Supportive Palliative Care
Other: Best Practice
Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
Other: Questionnaire Administration
Other: Quality-of-Life Assessment
Other: Survey Administration

First Posted Date: 2019-03-12

Last Posted Date: 2024-12-31

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 455

Registration Number: NCT03870750

Locations: 🇺🇸
Northwell Health Cancer Institute, New Hyde Park, New York, United States
🇺🇸
Stanford Cancer Institute Palo Alto, Palo Alto, California, United States
🇺🇸
University of California San Francisco, San Francisco, California, United States

and more 8 locations

Rituximab Hyaluronidase in Combination With Chemotherapy in Treating Aggressive B-cell Lymphoma in Uganda

Phase 1

Terminated

Conditions: Diffuse Large B-Cell Lymphoma
Burkitt Lymphoma
KSHV-associated Multicentric Castleman Disease

Interventions: Biological: Rituximab and Hyaluronidase Human
Drug: Cyclophosphamide
Drug: Vincristine
Drug: Methotrexate
Drug: Doxorubicin
Biological: Rituximab
Drug: Doxorubicin Hydrochloride
Drug: Prednisone
Drug: Etoposide

First Posted Date: 2019-03-06

Last Posted Date: 2024-01-03

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 18

Registration Number: NCT03864419

Locations: 🇺🇬
UCI-Fred Hutch Cancer Centre, Kampala, Uganda

Glucosamine and Chondroitin in Preventing Inflammation in Overweight Patients

Phase 1

Completed

Conditions: Healthy Subject
Overweight

Interventions: Dietary Supplement: Glucosamine
Other: Placebo

First Posted Date: 2019-02-01

Last Posted Date: 2019-02-01

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 2

Registration Number: NCT03827161

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy